Regentis Biomaterials Ltd. (RGNT)
NYSEAMERICAN: RGNT · Real-Time Price · USD
4.290
-0.460 (-9.68%)
At close: Jun 18, 2026, 4:00 PM EDT
4.212
-0.078 (-1.83%)
After-hours: Jun 18, 2026, 8:00 PM EDT

Regentis Biomaterials Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024
Period Ending
Dec '25 Dec '24
Selling, General & Admin
6.640.71
Research & Development
0.33-1.64
Total Operating Expenses
6.97-0.93
Operating Income
-6.970.93
Total Non-Operating Income (Expense)
-6.683.87
Pretax Income
-13.654.8
Net Income
-13.654.8
Net Income to Common
-13.654.8
Shares Outstanding (Basic)
11
Shares Outstanding (Diluted)
11
EPS (Basic)
-24.161.72
EPS (Diluted)
-24.161.72
Free Cash Flow
-1.38-0.64
Free Cash Flow Per Share
-2.43-1.13
EBITDA
-6.970.93
EBIT
-6.970.93
SEC Filings: 10-K · 10-Q